Literature DB >> 20213647

In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.

Stephan W Barth1, Karlis Briviba, Bernhard Watzl, Nicole Jäger, Doris Marko, Melanie Esselen.   

Abstract

Irinotecan is an anticancer agent that stabilizes topoisomerase I/DNA complexes. So far, no test system has been reported for directly determining irinotecan-induced stabilization of topoisomerase I/DNA complexes in organs in vivo. We adapted an 'in vivo complexes of enzyme to DNA' (ICE) bioassay to assess irinotecan activity in the stomach, duodenum, colon and liver of male Wistar rats after a single treatment with irinotecan (100 mg/kg body weight, intraperitoneally). This was compared to the control group receiving 0.9% sodium chloride intraperitoneally. In addition, the DNA strand breaking properties of irinotecan were measured in mucosal cells from the distal colon by single-cell gel electrophoresis (comet assay) to investigate the association of topoisomerase poisoning and DNA damage in vivo. A single dose of irinotecan significantly increased amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the irinotecan-treated group showed significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group. The ICE bioassay and the comet assay represent two test systems for investigating the impact of topoisomerase I poisons on DNA integrity in colon tissues of Wistar rats.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213647     DOI: 10.1002/biot.200900174

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  3 in total

1.  A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Authors:  Xiang Ling; Shousong Cao; Qiuying Cheng; James T Keefe; Youcef M Rustum; Fengzhi Li
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

2.  Formulation and evaluation of irinotecan suppository for rectal administration.

Authors:  Haiyang Feng; Yuping Zhu; Dechuan Li
Journal:  Biomol Ther (Seoul)       Date:  2014-01       Impact factor: 4.634

3.  Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.

Authors:  Ana Lucić Vrdoljak; Nino Fuchs; Anja Mikolić; Suzana Žunec; Irena Brčić Karačonji; Andreja Jurič; Ljerka Prester; Vedran Micek; Marijana Neuberg; Samir Čanović; Gordan Mršić; Nevenka Kopjar
Journal:  Molecules       Date:  2018-06-01       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.